Patent application number | Description | Published |
20080234504 | Processes for preparation of 9-haloacetamidominocyclines - The present invention provides substantially pure intermediates, 9-haloacetomidominocyclines, and process of preparing them that are useful for the preparation of glycylcyclines, specifically Tigecycline. | 09-25-2008 |
20090005453 | Crystalline forms of tigecycline and processes for preparation thereof - The present invention provides crystalline forms of Tigecycline, and methods of for preparation of crystalline forms and amorphous. | 01-01-2009 |
20090012047 | Crystalline forms of ibandronate sodium - Provided are crystalline forms of ibandronate sodium, as well as processes for the preparation thereof. | 01-08-2009 |
20090012316 | Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-Napathalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof - DNT-Oxal crystalline forms and processes for making DNT-Oxal crystalline forms are provided. | 01-08-2009 |
20090042839 | Crystalline forms of ibandronate sodium - Provided are crystalline forms of ibandronate sodium, as well as processes for the preparation thereof. | 02-12-2009 |
20090076272 | Polymorphs of eszopiclone malate - The present invention provides crystalline Eszopiclone malate form II, crystalline Eszopiclone form V, processes from preparing the crystalline Eszopiclone malate form II or V, pharmaceutical compositions comprising the crystalline Eszopiclone malate form II or V and methods of treating insomnia comprising administering the crystalline Eszopiclone malate form II or V. | 03-19-2009 |
20090099390 | Crystalline forms of ibandronic acid and processes for the preparation thereof - A crystalline ibandronic acid characterized by data selected from the group consisting of at least one of a powder x-ray diffraction pattern having peaks at about 4.1, 12.3 and 13.4±0.2 degrees two-theta and at least two more peaks selected from the group consisting of: 8.2, 11.3, 16.2 and 16.9 and 20.8±0.2 degrees two-theta, and by a powder X-ray diffraction pattern depicted in FIG. | 04-16-2009 |
20090118239 | Amorphous and crystalline forms of ibandronate disodium - Provided are amorphous and crystalline forms of ibandronate disodium, as well as processes for the preparation thereof. | 05-07-2009 |
20090118297 | POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF - Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof. | 05-07-2009 |
20090275653 | POLYMORPHIC FORMS OF LADOSTIGIL TARTRATE - The invention provides for solid state chemistry of ladostigil tartrate, particularly polymorphic forms of ladostigil tartrate, and processes for the preparation thereof. | 11-05-2009 |
20100113527 | CRYSTALLINE FORMS OF DEXLANSOPRAZOLE - Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof. | 05-06-2010 |
20100144887 | Crystalline solid rasagiline base - The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof. | 06-10-2010 |
20100145101 | Crystalline solid rasagiline base - The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof. | 06-10-2010 |
20100190859 | Citrate Salt of Rasagiline - The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof. | 07-29-2010 |
20110112316 | TIGECYCLINE CRYSTALLINE FORMS AND PROCESSES FOR PREPARATION THEREOF - The present invention relates to solid crystalline Tigecycline, and crystalline forms thereof. | 05-12-2011 |
20120003310 | DELAYED RELEASE RASAGILINE FORMULATION - Disclosed are formulations of rasagiline base which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. Also, disclosed are rasagiline citrate salt and the use and process of manufacture thereof. | 01-05-2012 |
20150038744 | Crystalline Solid Rasagiline Base - The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof. | 02-05-2015 |